Company news
Heartsciences Inc. (NASDAQ:HSCS) news
Heartsciences Inc. news releases on 6ix. Latest, Oct 6, 2026: HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device
Press releases & updates
HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device
October 6, 2026
HeartSciences Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
September 15, 2026
Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration
August 19, 2026
HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings, Provides Business Update and Reports Fiscal 2026 Financial Results
July 30, 2026
HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results
July 28, 2026
HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K
July 23, 2026
Fortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets
June 23, 2026
European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences’ Patent Portfolio to More Than 45 Granted Patents
June 11, 2026
HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
June 1, 2026
HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network
May 18, 2026
HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
May 5, 2026
HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
April 13, 2026
HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
March 24, 2026
HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
March 24, 2026
HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
March 16, 2026
University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
February 5, 2026
Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
January 29, 2026
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
December 15, 2025
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
December 15, 2025
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1
December 11, 2025
HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results
September 11, 2025
HeartSciences Announces Conference Participation and Investor Webinar
August 15, 2025
HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
July 24, 2025
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
June 4, 2025
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
June 3, 2025
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
May 29, 2025
HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
May 20, 2025
HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
May 8, 2025
HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
May 7, 2025
HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program
May 1, 2025
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
March 13, 2025
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
March 10, 2025
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
December 15, 2024
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
November 12, 2024
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
September 11, 2024
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
September 11, 2024
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
July 28, 2024
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
July 24, 2024
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
July 10, 2024
HeartSciences Regains Compliance with Nasdaq Listing Requirements
June 3, 2024
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
May 19, 2024
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
April 23, 2024
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
March 25, 2024
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
March 13, 2024
HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
March 11, 2024
HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology
March 5, 2024
HeartSciences Adds Key Advisor to its Scientific Advisory Board
February 25, 2024
HeartSciences Expands its Scientific Advisory Board
February 11, 2024
HeartSciences Appoints New Scientific Advisory Board Member
January 31, 2024
HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting
January 17, 2024